Publications & Works

Published journal articles indexed by SCI, SSCI, and AHCI

Articles Published in Other Journals

Diyabetik Nöropati

Galenos Tıp Dergisi , pp.24-35, 2003 (Peer-Reviewed Journal) Sustainable Development

Refereed Congress / Symposium Publications in Proceedings

Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.11-14 identifier

Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.384-386 identifier

Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.379-380 identifier

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.967-970 identifier

A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.951-953 identifier

Medulla oblongata volume measured from clinical routine T2-FLAIR scans is associated with disability progression in a multiple sclerosis real-world dataset

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.289-290 identifier

Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 26 - 28 October 2022, vol.28, pp.645-647 identifier

Identification of Therapeutic Lag in Multiple Sclerosis (1787)

American Academy of Neurology, United States Of America, 14 - 19 April 2020, vol.94, pp.1787

Determinants of Therapeutic Lag in Multiple Sclerosis (2059)

American Academy of Neurology, United States Of America, 14 - 27 April 2020, vol.94, pp.2059

Identification of Therapeutic Lag in Multiple Sclerosis

Annual Meeting of the American-Academy-of-Neurology, Toronto, Canada, 25 February - 01 March 2020

Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

American Academy of Neurology, United States Of America, 14 - 26 April 2020, vol.94, pp.2002

Determinants of therapeutic lag in relapsing multiple sclerosis

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.559-561 identifier

Predicting long-term sustained disability progression in multiple sclerosis

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.119-121 identifier

Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.186-188 identifier

Modifiers of the effectiveness of MS immunotherapies

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.791-793 identifier

Real-life outcomes of Ocrelizumab treatment from 3 multiple sclerosis centers in Turkey

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.751 identifier

Aggressive form of multiple sclerosis can be predicted early after disease onset

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.605-607 identifier

Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.63-65 identifier

Real world efficacy and safety of teriflunomide in multiple sclerosis: an observational study with four years follow-up

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.870 identifier

Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.786-788 identifier

MS cohorts and treatment utilization in academic centres in the Middle East

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.394 identifier

Therapeutic lag in relapsing multiple sclerosis

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.564-565 identifier

Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.912-914 identifier

Personalizing treatment effect based on patient's baseline profile: a statistical modelling approach applied to randomized clinical trial and observational study data

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.788-790 identifier

Real-world experience with Ocrelizumab in the MSBase Registry

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.539-540 identifier

Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, United States Of America, 4 - 10 May 2019, vol.92 identifier

Familial multiple sclerosis: comparing demographic and clinical characteristics with sporadic form

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31

Determinants of disability accumulation in secondary-progressive multiple sclerosis

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.30

RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the ’xxRELOMS-T’xx

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.100

Methylprednisolone concentration in milk and serum during and shortly after IV pulse therapy in patients with MS

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.978 identifier

Variability in scoring the functional system scores of the expanded disability status scale at clinics from different countries

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.155-156 identifier

RLS is an important and frequent cause of depression and anxiety in patients with MS: striking results of the 'RELOMS-T'

34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.174 identifier

De Novo Trigeminal Neuralgia Induced by Dalfampridine (4-aminopyridine):3 Cases

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 November 2017, vol.24, pp.379 identifier

Susac Syndrome: Clinical Features, Laboratory Testing and Treatment Responses of 3 Cases

10th Congress of the Pan-Asian-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Ho Chi Minh City, Vietnam, 23 - 25 November 2017, vol.24, pp.421 identifier

MULTIPL SKLEROZ’DA MORTALİTE

53. ULUSAL NÖROLOJİ KONGRESİ, Turkey, 24 - 30 November 2017

Susac Syndrome: Clinical features, Laboratory Testing and Treatment Response of 3 cases

10th Congress of the Pan-Asian Committe for Treatment and Research in Multiple Sclerosis, 23 - 25 November 2017

MULTİPL SKLEROZ’DA NATALİZUMAB TEDAVİSİ GERÇEK YAŞAM VERİSİ

53. ULUSAL NÖROLOJİ KONGRESİ, Antalya, Turkey, 24 - 30 November 2017, pp.229-230

Prognostic value of MRI activity in treatment failure

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.988-990 identifier

Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.71-73 identifier

Contribution of inflammation to disability accrual in primary progressive multiple sclerosis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.399-401 identifier

Methylprednisolone concentrations in breast milk and serum in patients with multiple sclerosis treated with IV pulse methylprednisolone

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.462 identifier

Risk of secondary progressive multiple sclerosis: a longitudinal study

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.109-112 identifier

The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.992-994 identifier

Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.361-363 identifier

Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.130-132 identifier

Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.325-327 identifier

Silent lesions on MRI - shifting goal post for treatment decisions in MS

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.393-394 identifier

Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.327-328 identifier

A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.395-397 identifier

Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases

7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25 - 28 October 2017, vol.23, pp.90-91 identifier

Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis

3rd Congress of the European-Academy-of-Neurology, Amsterdam, Netherlands, 01 June 2017, vol.24, pp.490 identifier

Wernicke ensefalopatisi: olgu sunumu

52. Ulusal Nöroloji Kongresi, Turkey, 25 November - 01 December 2016

Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.310 identifier

Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.62-63 identifier

Outcomes of pregnancy in neuromyelitis optica patients: turkish multicenter study data

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.405-406 identifier

Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.44-46 identifier

Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.829-832 identifier

Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.367-369 identifier

Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.602-603 identifier

Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.600-602 identifier

Individual response to disease modifying therapies: a global observational cohort study

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.358-360 identifier

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.337-338 identifier

Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul, South Korea, 19 - 21 November 2015, vol.22, pp.418-419 identifier

MS te yeni fenotipik patolojik ve klinik sınıflama

Ulusal Nöroloji kongresi, Turkey, 29 November - 01 December 2015

Lack of association between pulse steroid therapy and bone mineral density in patients with multiple sclerosis

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.773 identifier

Defining secondary progressive multiple sclerosis

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.798-800 identifier

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.100-102 identifier

Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.308-310 identifier

Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.258-259 identifier

Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.726-728 identifier

Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, Spain, 7 - 10 October 2015, vol.21, pp.237-238 identifier

NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.165 identifier

Evaluation of common criteria of progression of disability in a large observational cohort

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.62-63 identifier

Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.195-196 identifier

Seasonal variation of relapse rate in MS is latitude-dependent

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.218-219 identifier

Predictors of disability accrual in multiple sclerosis patients on first-line therapy

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.405 identifier

Independent predictors of time to relapse after CIS in high-risk patients

Joint ACTRIMS-ECTRIMS Meeting, Massachusetts, United States Of America, 10 - 13 September 2014, vol.20, pp.54 identifier

Head-to-head Comparisons of Interferon Beta and Glatiramer Acetate in Clinical Practice

6th Congress of the Pan-Asian-Committee-on-Treatment-and-Research-in-Multiple-Sclerosis (PACTRIMS), Kyoto, Japan, 6 - 08 November 2013, vol.20, pp.927 identifier

Factors associated with early hospital arrival in acute ischemic stroke patients

Joint Congress of European Neurology, İstanbul, Turkey, 31 May - 03 June 2014, vol.21, pp.353 identifier

Factors associated with early hospital arrival in acute ischemic stroke patients

Joint Congress of European Neurology, İstanbul, Turkey, 31 May - 03 June 2014, vol.261 identifier

Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.55-56 identifier

Defining secondary progressive multiple sclerosis: is it possible to diagnose early?

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.38 identifier

Predictors of 12-month confirmed disability progression after onset of clinically isolated syndrome (CIS) suggestive of multiple sclerosis

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.13-15 identifier

Symptomatology of multiple sclerosis relapses varies in relation to demographic and clinical factors

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.112-114 identifier